Description: Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.
Home Page: www.theranexus.com
60, Avenue Rockefeller
Lyon,
69008
France
Phone:
33 1 88 89 70 31
Officers
| Name | Title |
|---|---|
| Mr. Franck Mouthon | Co-Founder & Executive Chairman |
| Mr. Mathieu Charvériat | Co-Founder, CEO & Director |
| Mr. Julien Veys | Chief Business Officer & Director |
| Mr. Thierry Lambert | CFO and Administrative & Financial Director |
| Ms. Francoise Vincent-Larrode | Director of Human Resources |
| Ms. Marie Sebille | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8994 |
| Price-to-Sales TTM: | 1.6557 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |